论文部分内容阅读
本文意就早期乳腺癌(T_1或T_2期,且均无局部淋巴结转移)老年女性随机接受或单一他莫昔芬或联合乳腺局部照射治疗对其远期预后,如无肿瘤复发者存活率以及局部复发风险等进行了对照分析。对象与方法769例早期乳腺癌(均属T_1或T_2期,且瘤体直径均≤5cm)老年女性,年龄均≥50岁。研究中分为随机双盲接受单一他莫昔芬20mg/d治疗组383例,或联用他莫昔芬20mg/d加乳腺局部照射治疗组386例,两组他莫昔芬用药均持续5年,联合治疗组接受乳腺局部照射共12周。尔后人均随访5．6年,旨在观察分析两组主要终点如无肿瘤复发者存活率、死亡率,以及次要终点包括肿瘤局部复发、腋窝淋巴结转移和累计存活率等预后间差异。
This article is intended to evaluate the long-term prognosis of elderly women with early-stage breast cancer (stage T_1 or stage T_2, with no local lymph node metastases) or with local exposure to tamoxifen alone or in combination with local breast irradiation such as survival without tumor recurrence and local Recurrence risk were analyzed. Subjects and Methods 769 cases of early breast cancer (both T_1 or T_2, and tumor diameter ≤ 5cm) elderly women, mean age ≥ 50 years. The study was divided into a randomized double-blind to accept a single tamoxifen 20mg / d treatment group 383 cases, or combined with tamoxifen 20mg / d plus breast irradiation group 386 cases, two groups of tamoxifen medication were sustained 5 Year, the combined treatment group received local breast irradiation for 12 weeks. A mean follow-up of 5.6 years was followed to observe and analyze the survival rates and mortality rates of the two primary end points, such as those without tumor recurrence, and the secondary outcomes including local tumor recurrence, axillary lymph node metastasis and cumulative survival.